Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer [0.03%]
德瓦鲁单抗联合白蛋白紫杉醇，以及卡博替尼或奥莱珠单抗治疗局部晚期或转移性三阴乳腺癌患者的一项研究
Peter Schmid,Cynthia X Ma,Yeon Hee Park et al.
Peter Schmid et al.
Purpose: Triple-negative breast cancer (TNBC) is a heterogeneous disease with high recurrence rates and poor prognosis, often requiring multiple therapies. BEGONIA was a phase Ib/II, multiarm, platform study evaluating th...
Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in patients with locally advanced NSCLC [0.03%]
Durvalumab治疗局部晚期NSCLC患者的效应T细胞序贯活化作为疗效生物标志物研究
Atsuto Mouri,Hirotsugu Kenmotsu,Hiroshi Kagamu et al.
Atsuto Mouri et al.
Background: Durvalumab therapy following concurrent chemoradiotherapy (cCRT) improves progression-free survival (PFS) in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). In this prospecti...
Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine [0.03%]
针对高级别髓系肿瘤的BCL-xL和BCL-2双重抑制：Navitoclax、Venetoclax与Decitabine联合用药剂量爬坡1期临床试验
Evan C Chen,Yiwen Liu,Hayden L Bell et al.
Evan C Chen et al.
Background: The BCL-2 inhibitor venetoclax in combination with a hypomethylating agent is effective treatment for most subtypes of acute myeloid leukemia (AML), but it is less effective for other high-risk myeloid neoplas...
PiggyBac-engineered membrane-bound IL-7 TILs combined with anti-PD-1 antibody demonstrates efficacy in recurrent ovarian cancer: a first-in-human phase 1 trial [0.03%]
基因工程膜结合型IL-7肿瘤浸润淋巴细胞联合抗PD-1抗体治疗复发性卵巢癌的首次人体I期临床试验显示有效
Jing Guo,Yuliang Wu,Wei Huang et al.
Jing Guo et al.
Purpose: Recurrent ovarian cancer (rOC) remains an unmet need. This first-in-human phase 1 trial evaluated GC203, an autologous tumor-infiltrating lymphocyte (TIL) product genetically modified via piggyBac transposon to o...
A first-in-pediatric study of ALRN-6924, a novel stapled-peptide dual MDM2/MDMX inhibitor, for children with advanced hematologic and solid malignancies [0.03%]
ALRN-6924（一种新颖的环肽型双MDM2/MDMX抑制剂）治疗儿童晚期血液系统恶性肿瘤和实体瘤患者的首次临床研究
David S Shulman,Kieuhoa T Vo,Frank M Balis et al.
David S Shulman et al.
Purpose: ALRN-6924 is a stapled peptide that disrupts MDM2/MDMX-mediated inhibition of p53. We evaluated safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ALRN-6924 in children with advanced malignan...
Design, Preclinical Evaluation, and Clinical Translation of [68Ga]Ga/[177Lu]Lu-JH120061, A Novel Radiopharmaceutical Targeting CXCR4 [0.03%]
一种新型靶向CXCR4放射性药物[JH120061]的创新设计、临床前评估及临床转化研究
Guochang Wang,Tianrui Kang,Yumeng Peng et al.
Guochang Wang et al.
Purpose: We designed and synthesized a novel compound targeting CXCR4, JH120061. Using clinically established Pentixafor and Pentixather as references, we evaluated the potential of [68Ga]Ga/[177Lu]Lu-JH120061 in a series...
Rongxin Xiao,Jiali Yu,Yijian Yan et al.
Rongxin Xiao et al.
B7-H4 (also known as B7x or B7S1) is a member of the B7 family and is expressed in a broad spectrum of malignancies, with particularly elevated levels in tumors arising from female reproductive organs. Functionally, B7-H4 suppresses T cell ...
A New CA19-9 Cutoff Value Identifies Lewis Antigen Status and Refines Prognostic Stratification in PDAC [0.03%]
一个新的CA19-9截断值可确定Lewis抗原状态并细化胰腺导管腺癌的预后分层
Chia-Ming Yeh,Chih-Chuan Yu,An-Fu Lee et al.
Chia-Ming Yeh et al.
Purpose: Carbohydrate antigen 19-9 (CA19-9) has limited utility in the ∼10% of patients with pancreatic ductal adenocarcinoma (PDAC) who are Lewis-negative CA19-9 "nonproducers" (FUT3-null). This study aims to define the...
Exploratory analysis of PTEN deficiency by immunohistochemistry from the Phase III CAPItello-291 trial [0.03%]
CAPItello-291三期试验的PTEN缺失免疫组化探索性分析
Komal Jhaveri,Hope S Rugo,Javier Cortés et al.
Komal Jhaveri et al.
Purpose: The PI3K/AKT pathway is frequently activated in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, with loss of phosphatase and tensin homolog (PTEN) a...
Phenotypic and Functional Characteristics of CD8+ T cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma [0.03%]
预测黑色素瘤过继性细胞治疗效果的CD8+t细胞表型和功能特征
Joachim S Granhøj,Sigrid M H Mannering,Kasper Madsen et al.
Joachim S Granhøj et al.
Purpose: Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) is a highly personalized cancer immunotherapy. In the randomized Phase III clinical trial (TIL-NKI/CCIT), TIL therapy significantly improved progres...